Earnings Insights

AI-generated analysis of quarterly earnings, concall highlights, and financial performance across Indian listed companies.

How to use these insights

Each article is built from earnings call transcripts and structured rank signals. Start with the latest summary, then open the stock page for the full company view, the concall page for quarter-by-quarter commentary, and the rankings dashboard to compare peers.

Kanpur Plastipack Q1 FY26 earnings call: Revenue & Margins | Arthneeti

Q1 FY26

Acquisitions like Valex Ventures to add INR 4-5 crore top line on a consolidated basis. Key concall takeaways from Kanpur Plastipack Ltd's Q1 FY26 earnings…

26 May 2026

Kamat Hotels (India) Q3 FY26 earnings call: Revenue & Margins | Arthneeti

Q3 FY26

Seasonal and regional variations affect occupancy, with leisure destinations taking longer (6-9 months) to achieve optimal utilization (~70% occupancy). Key…

26 May 2026

Kamat Hotels (India) Q2 FY26 earnings call: Revenue & Margins | Arthneeti

Q2 FY26

Despite recent revenue dips due to monsoon, renovations, and subsidiary performance, management is confident of crossing INR 400 crore revenue in FY 2026. Key…

26 May 2026

Kamat Hotels (India) Q1 FY26 earnings call: Revenue & Margins | Arthneeti

Q1 FY26

The company plans to expand room inventory from approximately 1,850 to 2,500 operational rooms within the year, a ~35% increase. Key concall takeaways from…

26 May 2026

Kamat Hotels (India) Q4 FY25 earnings call: Revenue & Margins | Arthneeti

Q4 FY25

65%; major cities like Mumbai and Delhi can see occupancies in the 70-80% range. Key concall takeaways from Kamat Hotels (India) Ltd's Q4 FY25 earnings call…

26 May 2026

KAMATHOTEL Q3 FY25 earnings call: Margins & Order Book | Arthneeti

Q3 FY25

Direct booking channels and repeat customers (34% repeat rate) contribute to sustainable revenue growth. Key concall takeaways from KAMATHOTEL's Q3 FY25…

26 May 2026

Jyoti Resins and Adhesives Q1 FY26 earnings call: Revenue & Margins | Arthneeti

Q1 FY26

Current Q1 FY26 volume showed a 3% de-growth, but efforts ongoing to recover in remaining quarters (Page 27). Key concall takeaways from Jyoti Resins and…

26 May 2026

Jyoti Resins and Adhesives Q4 FY25 earnings call: Revenue & Margins | Arthneeti

Q4 FY25

The goal is to reach INR 500 crore revenue by FY27 through a mix of geographic expansion and deepened penetration in existing markets. Key concall takeaways…

26 May 2026

Jindal Drilling & Industries Q3 FY26 earnings call: Revenue & Margins | Arthneeti

Q3 FY26

. Key concall takeaways from Jindal Drilling & Industries Ltd's Q3 FY26 earnings call — and how it ranks against sector peers.

26 May 2026

Jindal Drilling & Industries Q1 FY26 earnings call: Revenue & Margins | Arthneeti

Q1 FY26

Company currently has a net cash position of INR112 crores and strong operational profitability. Key concall takeaways from Jindal Drilling & Industries Ltd's…

26 May 2026

Jindal Drilling & Industries Q3 FY25 earnings call: Revenue & Margins | Arthneeti

Q3 FY25

Market leadership and consolidation of rigs into Jindal Drilling will potentially improve EBITDA margins further from current 30-35%. Key concall takeaways…

26 May 2026

Jain Irrigation Systems Q3 FY26 earnings call: Revenue & Margins | Arthneeti

Q3 FY26

Retail sales showed strong growth (24% this quarter), and future growth will be primarily retail-driven with better working capital efficiency. Key concall…

26 May 2026

Jain Irrigation Systems Q4 FY25 earnings call: Revenue & Margins | Arthneeti

Q4 FY25

Hi-tech division (micro irrigation and tissue culture) to grow strongly, with tissue culture potentially growing 20%-30%. Key concall takeaways from Jain…

26 May 2026

Jagsonpal Pharmaceuticals Q3 FY26 earnings call: Revenue & Margins | Arthneeti

Q3 FY26

Margins improved with operational resilience; EBITDA margins were 22.6% for nine months FY '26. Key concall takeaways from Jagsonpal Pharmaceuticals Ltd's Q3…

26 May 2026

Jagsonpal Pharmaceuticals Q1 FY26 earnings call: Revenue & Margins | Arthneeti

Q1 FY26

Around 9%-10% of growth is organic, with the rest from full-quarter contribution of acquisitions. Key concall takeaways from Jagsonpal Pharmaceuticals Ltd's Q1…

26 May 2026

Jagsonpal Pharmaceuticals Q3 FY25 earnings call: Revenue & Margins | Arthneeti

Q3 FY25

Growth drivers include approximately one-third volume growth, one-third price increases (3-5%), and one-third new product launches. Key concall takeaways from…

26 May 2026

Insecticides India Q3 FY26 earnings call: Revenue & Margins | Arthneeti

Q3 FY26

Emphasis on disciplined capital allocation with focus on increasing capital efficiency and improving organizational revenue, ROCE, and ROE by 6-7% over three…

26 May 2026

Insecticides India Q2 FY26 earnings call: Revenue & Margins | Arthneeti

Q2 FY26

150 crore sales in exports this year. Key concall takeaways from Insecticides India Ltd's Q2 FY26 earnings call — and how it ranks against sector peers.

26 May 2026

Insecticides India Q4 FY25 earnings call: Revenue & Margins | Arthneeti

Q4 FY25

10-12 crore in FY'26, with potential multiplication in subsequent years (Page 9-12). Key concall takeaways from Insecticides India Ltd's Q4 FY25 earnings call…

26 May 2026

BirlaNu Q4 FY25: Revenue ₹100 Cr | Arthneeti

Q4 FY25

OPVC plant Phase 1 capacity to be around 5,000 tons/year with revenue potential north of Rs.100 crore. Key concall takeaways from BirlaNu Ltd's Q4 FY25…

26 May 2026

Arthneeti Pro · Annual

Every earnings call this season,
for less than your morning chai

Every earnings call, ranking and concall Q&A across all four results seasons.

Secure Razorpay payment · instant access